key: cord-1006231-eb7t7c9f authors: Del Papa, Nicoletta; Sambataro, Gianluca; Minniti, Antonina; Pignataro, Francesca; Caporali, Roberto title: Novel COronaVirus Disease 2019 (COVID-19) epidemic: What are the risk for systemic sclerosis patients? date: 2020-05-05 journal: Autoimmun Rev DOI: 10.1016/j.autrev.2020.102558 sha: 960755cc13b537ad48d8e4f4419614ad673d756b doc_id: 1006231 cord_uid: eb7t7c9f nan In December 2019 in the Hubei province of China began a pandemic outbreak sustained by a novel coronavirus named Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2). The syndrome sustained by this virus has been named COronaVirus Disease 2019 (COVID-19) and respiratory illness is the dominant clinical manifestation [1] . From its onset, the virus rapidly spread in the world, leading the World Health Organization officially to declare a pandemic state on March 11, 2020, Great importance in the mortality associated with coronaviruses infection has been given to the concomitant comorbidities of the patients. For COVID-19, a close correlation has been found with J o u r n a l P r e -p r o o f Journal Pre-proof diabetes, hypertension, cardiovascular disease, whereas chronic obstructive lung disease, chronic liver disease and malignancies were reported in about 1-7% of patients who died [2] . Immunocompromised patients are rarely reported in SARS-1 and MERS cohorts [3] [4] [5] and mainly referred to patients with active cancer under chemotherapy (about 5-6% of patients). Particularly, the prevalence of coronaviruses infection in patients with autoimmune diseases is lacking in previous literature. This issue raises several concerns regarding the utility to continue immunosuppressive agents in this cohort of patients during outbreak [6, 7] . Recently, Monti et al. [8] reported that patients with rheumatoid arthritis treated with biological DMARDs or targeted synthetic DMARDs did not seem to be at increased risk of life-threatening complications from SARS-CoV-2 compared with general population. Similarly, recent publications reported no cases of complicated SARS-CoV-2 related pneumonia in inflammatory bowel diseases, even in those patients under immunosuppressive treatment [9, 10] . Whilst these figures are reassuring, the scenario could be quite different with regard to patients suffering from systemic sclerosis (SSc). SSc is a rare multifaceted autoimmune disorder characterized by inflammatory, vascular, and fibrotic processes resulting in skin fibrosis and multiple organ manifestations [11] . Lung involvement, i.e, interstitial lung disease (ILD) and pulmonary hypertension, is a common manifestation and develops in up to 75% of patients with SSc overall. To date, ILD represents the main cause of death in these patients [12] . Although at the moment the treatment of SSc is not well established, currently therapy of SSc patients focuses on immunosuppressant agents, particularly cyclophosphamide and mycophenolate mofetil. Furthermore some patients undergo conditioning immunosuppressive therapy before autologous stem cell transplantation (ASCT) [12, 13] . More recently, consistent data have been published on the potential effectiveness of rituximab and anti-interleukin (IL) 6 receptor blocker tocilizumab in the improvement/stabilization of SSc ILD [13] . Since the lung disease and immunosuppression are interleukin -17 (IL-17) production with a specific inhibition on Th17 cells [13] . Then, we can speculate that suppression of pro-inflammatory cytokines and T-cell activities by steroids and other immunosuppressive agents might be protective, even in SSc patients . Broadly speaking, there is some evidence that the use of anti-inflammatory agents, and namely of corticosteroids, may induce some improvement in the acute phase of this and other viral infections [17] . The patients with pre-existing cardiovascular disease appear to have heightened vulnerability to develop COVID-19 and tend to have more severe disease with worse clinical outcomes [18] . Cardiac involvement, due to both primary myocardiopathy and secondary to pulmonary hypertension, is common in SSc and associated with increased morbidity and mortality [19] . At the moment we do not know the impact of pre-existing scleroderma cardiac involvement on COVID-19 course. Finally, it is highly desirable that future studies may be specifically addressed to the clinical course and outcome of COVID-19 in SSc patients under chronic immunosuppressive therapies and with pre-existing heart and pulmonary involvement. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 outbreak in China LANCOVID-19). Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis Clinical Features and short-term outcomes of 144 patients with SARS in the greater Toronto area Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease State of Knowledge and data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in humans COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev What is the role of rheumatologists in the era of COVID-19? Implications of COVID-19 for patients with preexisting digestive diseases Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy Systemic Sclerosis -associated interstitial lung disease Management of systemic sclerosis: the first five years COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Pathological findings of COVID-19 associated with acute respiratory distress syndrome COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience COVID-19: Risk Groups, Mechanistic Insights, and Challenges Systemic sclerosis and the heart